Effect of unconjugated anti-CD22 mAb G5/44 and CMC-544 on RL BCL xenografts. Effect of unconjugated anti-CD22 mAb G5/44 on developing (A) or small but established (B) RL BCL xenografts. In addition, CMC-544 was also administered as 3 doses, 1 every 4 days treatments starting day 23 to established RL BCL xenograft-bearing mice that had been pretreated with unconjugated G5/44 over a period of 21 days (B). CMC-544 was also administered on day 1, then again on days 5 and 9, as a positive control. G5/44 dose is shown in antibody protein equivalents and CMC-544 dose is shown in CalichDMH equivalents. Error bars show standard devisation (SD).